A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia.

Trial Profile

A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Pharmacogenomic; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 500 to 550 as reported by EudraCT.
    • 04 Jul 2012 Additional trial location (Czech Republic) identified as reported by EudraCT.
    • 17 Mar 2009 Status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top